SwitzerlandHealthcare and life sciences2026 – ongoingLonza
AI-guided biologics batch-process optimization
Lonza reported 15% higher output after experts acted on AI analysis of batch histories
Problem
Lonza needed to identify which manufacturing conditions affected biologics output. Relevant signals were distributed across historical batch records.
Approach
Lonza applied AI to more than 100 historical batches for a large pharmaceutical customer. The analysis identified relationships between process parameters and production outcomes. Manufacturing science and technology experts used those findings to make process decisions with the customer.
Results
Takeaway
The reported gain followed expert decisions based on AI findings. Lonza did not name the customer or disclose the measurement period.
Categories
- Size
- Large enterprise
- Industry
- Healthcare and life sciences
- Business function
- Production and quality
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Pharma Manufacturing reported Lonza executives' descriptions of AI-guided manufacturing. CEO Wolfgang Wienand attributed a 15% output increase to expert interventions informed by AI analysis of historical batches.
Full details are in the original sources.
